Immunohistochemical classification was available for 23 pts: Luminal A tumours were not represented; there were 43.5% of pts with Luminal B HER-2 negative tumours, and 43.4% pts with either HER-2 positive (30.4%) or triple-negative (13%) tumours. Here, ERBB2 is linked to neoplasm.